814 related articles for article (PubMed ID: 27761751)
1. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
2. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort.
Tarricone E; Ghirardello A; Rampudda M; Bassi N; Punzi L; Doria A
J Immunol Methods; 2012 Oct; 384(1-2):128-34. PubMed ID: 22884621
[TBL] [Abstract][Full Text] [Related]
3. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
4. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
Srivastava P; Dwivedi S; Misra R
Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Chinoy H; Fertig N; Oddis CV; Ollier WE; Cooper RG
Ann Rheum Dis; 2007 Oct; 66(10):1345-9. PubMed ID: 17392346
[TBL] [Abstract][Full Text] [Related]
7. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
8. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
9. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
[TBL] [Abstract][Full Text] [Related]
10. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
Cavazzana I; Fredi M; Ceribelli A; Mordenti C; Ferrari F; Carabellese N; Tincani A; Satoh M; Franceschini F
J Immunol Methods; 2016 Jun; 433():1-5. PubMed ID: 26906088
[TBL] [Abstract][Full Text] [Related]
11. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
16. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
17. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
[TBL] [Abstract][Full Text] [Related]
18. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis.
Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Franceschini F; Quinzanini M; Tincani A; Ross SJ; Chan JY; Pauley BA; Chan EK; Satoh M
Arthritis Res Ther; 2012 Apr; 14(2):R97. PubMed ID: 22546500
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
[TBL] [Abstract][Full Text] [Related]
20. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]